Jónas Einarsson

Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway.

Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway.

Biomolex AS develops and delivers imaging systems for digital autoradiography. It offers Biomolex 700, a digital imager for protein micro-array analysis, including kinase analyses, protein interaction assays, single istotope deoxyribonucleic acid array analyses, micro analyses; and tissue imaging applications, such as foreign genetic material delivery, tissue specific distributions, uptake of antibodies, and uptake of labeled bio-molecules. The company was founded in May 2001 and is headquartered in Oslo, Norway.

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.

Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway.

Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway.